Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lot-to-lot consistency of a 23-valent pneumococcal polysaccharide vaccine
ChiCTR2000032861Phase 4Not yet recruiting
- Sponsor
- Guangxi Center for Disease Control and Prevention
- Start
- May 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease (3 arms), sponsored by Guangxi Center for Disease Control and Prevention. Primary endpoint: Serum IgG antibody of 23 pneumococcal serotypes. Planned start May 2020; status: not yet recruiting.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on ChiCTR2000032861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032861.